Elanco Director Purchases 40,000 Shares for $936,000
Key Points
The purchase was valued at $936,000.
This investment increased the insider's direct equity position by 27%.
Analysts are generally bullish on Elanco stock, with a median one-year price target of $32.
Lawrence Erik Kurzius, Director at Elanco Animal Health(NYSE:ELAN), purchased 40,000 shares of common stock at $23.40 per share on Aug. 20, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $936,000 |
| Shares purchased | 40,000 |
| Post-transaction shares (directly held) | 188,647 |
| Post-transaction value | $4.4 million |
Transaction value based on SEC Form 4 weighted average purchase price ($23.40); post-transaction value based on Aug. 20, 2026, market close ($23.56).
Key questions
- How significant is this purchase relative to the insider's existing position?
This acquisition of 40,000 shares represents a 27% expansion of the insider's direct holdings, increasing the total stake from 148,647 shares to 188,647 shares. - What were the specific execution details of this trade?
The purchase was executed at a weighted average price of $23.40 per share, with individual transaction prices ranging from $23.385 to $23.40 on Aug. 20, 2026. - What is the current scale of the company's operations?
Elanco, an animal health company based in Indianapolis, maintains a market capitalization of $12.2 billion and generated $5 billion in trailing twelve-month revenue as of the Aug. 20, 2026, market close. - Does the insider hold other forms of equity in the firm?
Beneficial ownership is held exclusively through direct holdings, which total 188,647 shares, as the reporting person does not maintain any indirect positions in the issuer.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-20) | $23.56 |
| Market Capitalization | $11.8 billion |
| Revenue (TTM) | $5 billion |
| Net Income (TTM) | -$199 million |
Company Snapshot
- Elanco Animal Health develops, manufactures, and commercializes a comprehensive portfolio of animal health solutions for both companion animals and livestock, including preventative parasiticides, vaccinations, and therapeutic treatments under recognized brands such as Seresto, Advantage, Advantix, and Advocate.
- The company generates revenue through the sale of pharmaceutical and health products for companion animals and livestock producers, leveraging a diversified product portfolio that addresses both preventative and therapeutic animal health needs across multiple market segments.
- Elanco serves veterinarians, pet owners, livestock producers, and agricultural operations globally, positioning itself as a comprehensive provider of animal health solutions across companion animal and production animal markets.
Elanco Animal Health is a leading global animal health company with approximately 9,400 employees and TTM revenues of $5 billion, demonstrating substantial scale in the specialized pharmaceutical and animal health sector. The company maintains a diversified business model spanning companion animal preventative care, therapeutic treatments, and livestock health solutions, enabling revenue generation across multiple customer segments and geographies. Elanco's competitive positioning is strengthened by its portfolio of established brands and comprehensive product offerings that address critical animal health needs in both companion and production animal markets.
What this transaction means for investors
The recent purchase of shares by Kurzius is a bullish signal for shareholders about the company's potential direction. The Elanco stock price has climbed 40% over the past 12 months, while the S&P 500 is up 18.7% over the same period. With how the stock price has performed, it would be understandable if the executive took some profits off the table. But the purchase shows that not only does Kurzius want to hold on to his shares, he wants to add more. And what he added to his totals is a substantial number of shares.
Along with Kurzius, analysts also appear bullish on the stock. According to CNN, of the 18 analysts covering Elanco, 89% rate it a buy, while only 11% rate it a hold. It has no sell ratings from that group. And from that group, the median price target over the next 12 months is $32, representing a potential gain of 31.3% from today's price. The group's highest target is $34, representing a slightly higher potential gain than the median target of nearly 40%. The group's lowest price target is $26, which would still represent a 6.7% gain. The insider buying and the price targets provide two bullish signals for shareholders of what may be ahead in the near term.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.